Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04505826
What this trial is testing

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
Olema Pharmaceuticals, Inc. 153
Very early researchStudy completedNCT02802748
What this trial is testing

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 60
Testing effectiveness (Phase 2)Study completedNCT04603183
What this trial is testing

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Who this might be right for
Breast Cancer Metastatic
MedSIR 162
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Not applicableStudy completedNCT05853432
What this trial is testing

A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

Who this might be right for
HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 157
Not applicableLooking for participantsNCT07215364
What this trial is testing

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

Who this might be right for
Early-stage Breast Cancer
Spanish Breast Cancer Research Group 74
Early research (Phase 1)Looking for participantsNCT07137871
What this trial is testing

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Who this might be right for
Breast Cancer Metastatic
The University of Texas Health Science Center at San Antonio 35
Not applicableStudy completedNCT07363434
What this trial is testing

A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 335
Not applicableLooking for participantsNCT06856200
What this trial is testing

Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Who this might be right for
Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
Fudan University 36
Not applicableLooking for participantsNCT04968964
What this trial is testing

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 55
Testing effectiveness (Phase 2)Looking for participantsNCT05297617
What this trial is testing

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

Who this might be right for
Breast Cancer
UNICANCER 696
Testing effectiveness (Phase 2)Looking for participantsNCT06389006
What this trial is testing

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 79
Early research (Phase 1)Active Not RecruitingNCT07557004
What this trial is testing

SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 30
Not applicableEnded earlyNCT03786107
What this trial is testing

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Who this might be right for
Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerMetastatic Cervical Cancer
Puma Biotechnology, Inc. 1,583
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Large-scale testing (Phase 3)Active Not RecruitingNCT02947685
What this trial is testing

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Breast CancerEstrogen Receptor Positive Breast Cancer
Alliance Foundation Trials, LLC. 518
Testing effectiveness (Phase 2)Looking for participantsNCT06914440
What this trial is testing

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Xijing Hospital 27
Testing effectiveness (Phase 2)Study completedNCT02675231
What this trial is testing

Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CancerHER-2 Positive Breast Cancer
Eli Lilly and Company 237
Testing effectiveness (Phase 2)Looking for participantsNCT07581834
What this trial is testing

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Who this might be right for
Breast DiseasesBreast NeoplasmsDalpiciclib+3 more
Fujian Cancer Hospital 2,000
Post-approval studies (Phase 4)Ended earlyNCT04657679
What this trial is testing

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

Who this might be right for
Breast Cancer
Georgetown University 21
Next Page